Table 3.
Potential vaccine for COVID-19 in clinical trials.
| Vaccine name | Platform | Type of vaccine | Company name | Clinical phase | References |
|---|---|---|---|---|---|
| ChAdOx1 nCoV-19 | Non-replicating viral vector | ChAdOx1 | University of Oxford/AstraZeneca | Phase-III (24ISRCTN8995144) | (World Health Organization (WHO, 2020f) |
| mRNA-1273 | RNA | Lipid nanoparticle dispersion encapsulated mRNA | Moderna therapeutics | Phase-III (NCT04470427) | (World Health Organization (WHO, 2020f) |
| Sinovac | Inactivated viral vaccine | Inactivated viral vaccine | Sinovac | (NCT04456595) | (World Health Organization (WHO, 2020f) |
| Beijing Institute of Biological Products/Sinopharm | Inactivated | Inactivated | Beijing Institute of Biological Products/Sinopharm | (ChiCTR2000034780) | (World Health Organization (WHO, 2020f) |
| Wuhan Institute of Biological Products/Sinopharm | Inactivated viral vaccine | Inactivated vaccine | Wuhan Institute of Biological Products/Sinopharm | (ChiCTR2000034780) | (World Health Organization (WHO, 2020f) |
| BioNTech/Fosun Pharma/Pfizer | RNA | 3 LNP-mRNAs | BioNTech/Fosun Pharma/Pfizer | (NCT04368728) | (World Health Organization (WHO, 2020f) |
| Ad5-nCoV | Non-replicating viral vector | Adenovirus type 5 vector | CanSino biologics | Phase-II (ChiCTR000031781) | (World Health Organization (WHO, 2020f) |
| RBD-Dimer | Protein Subunit | Adjuvanted recombinant protein (RBD-Dimer) | Anhui ZhifeiLongcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | (NCT04466085) | (World Health Organization (WHO, 2020f) |
| INO-4800 | DNA | DNA plasmid encoding S protein delivered by electroporation | Inovio Pharmaceuticals, CEPI | Phase-I (NCT04336410) | (National Institutes of Health (NIH, 2020) |
| LV-SMENP-DC | Antigen-specific CTLs | Dendritic cells modified with a lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs | Shenzhen Geno-Immune Medical Institute | Phase-I Phase-II (NCT04276896) | (National Institutes of Health (NIH, 2020) |
| Covid-19/aAPC | Pathogen-specific aAPC | aAPCs modified with a lentiviral vector expressing synthetic minigene based on domains of selected viral proteins | Shenzhen Geno-Immune Medical Institute | Phase-I (NCT04299724) | (National Institutes of Health (NIH, 2020) |